| Catalog No. | HY428026 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Functional assay, Research in vivo |
|---|
| Isotype | Fusion - [ACVR2A (activin A receptor type 2A, ActR-II, ActRIIA)]2 - IGHG1 Fc (Fragment constant) |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | EDF, Erythroid differentiation protein, Activin beta-A chain, INHBA, Inhibin beta A chain |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P08476 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | ACE-011, ACTRIIA-Fc, MK7962, MK-7962, MK7962, Sotatercept(USAN/INN), SOTATERCEPT-CSRK, WINREVAIR, CAS:1001080-50-7 |
|---|
| Background | Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions. |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
